PDCD1 and neoplasm: Nine studies tested a PD-1 inhibitor as a single agent, while the Keynote 021 study tested pembrolizumab plus chemotherapy vs chemotherapy alone.17 Non–small cell lung cancer was the most common tumor type studied (6 RCTs [50% of the cohort]).